Subject Index

The letters ‘f’ and ‘t’ following the locators refer to figures and tables respectively.

A
AAP, see American Academy of Pediatrics (AAP)
ABCs, see Active Bacterial Core surveillance (ABCs)
ABPA, see Allergic Bronchopulmonary Aspergillosis (ABPA)
Abscess clinical presentation, 307 
epidemiology, 307 
microbiology, 307 
treatment incision and drainage, 307–308
Absolute neutrophil count (ANC), 365–366
ABU, see Asymptomatic bacteriuria (ABU)
ACHSP, see Advisory Committee for HIV and STD prevention (ACHSP)
Acinetobacter baumannii, 56–57
beta-lactams, resistance, 56 
glycyclines (tigecycline), 56
ACIP, see Advisory Committee on Immunization (ACIP)
ACL, see Anterior cruciate ligament (ACL) reconstruction
Active Bacterial Core surveillance (ABCs), 2, 12
Acute upper respiratory illnesses (ARIs), 14
See also Upper Respiratory Infections (URIs)
Adamantanes, 85–86
amantadine/rimantadine dosing recommendations, 85t
side effects, 85–86
Advisory Committee for HIV and STD prevention (ACHSP), 196
Advisory Committee on Immunization (ACIP), 98
Agency for Healthcare Research and Quality, 380
AHA, see American Heart Association (AHA) guidelines
Alanine transaminase (ALT), 258
Allergic bronchopulmonary aspergillosis (ABPA), 133–134
Allergic rhinitis, 154, 156–157
ALT, see Alanine transaminase (ALT)
American Academy of Pediatrics (AAP), 102, 152, 155, 157, 286, 290
American Heart Association (AHA) guidelines, 270
American Society of Clinical Oncology, 365
Aminoglycosides, 53 infections, treatment, 53
drug exclusion, 53 
gentamicin/tobramycin/amikacin, 53
Amphotericin B, 127, 140–146, 232, 277, 289
candidal infections, dosages for, 141t
Amsel’s criteria, 218
ANC, see Absolute neutrophil count (ANC)
Anterior cruciate ligament (ACL) reconstruction, 317
Antibacterial vaccines, 380–381
Antibiotic prophylaxis, endocarditis, 275–276
AHA guidelines, 275 cardiac conditions, risk associated, 276t
iatrogenic complications, 276
regimens for dental procedure, 276t
Antibiotics awareness/uses, 15f
in children/adolescent, 14 controlled trials, 18t–20t
educational interventions, 15
Get Smart: Know When Antibiotics Work, 16
migration/lack of regulation, uses, 382–384
internet vendors, 383
Latin American cultures, 383
multidrug-resistant tuberculosis, 382
Antibiotics (cont.)
- prescription medication on internet, 383
- self-diagnosis/self-medication, risk factors, 382
- travel and immigration, 382
- in nonmedical settings, 384–386
- antibiotics in agriculture, 385
- multidrug-resistant *E. coli*, 385
- “nontherapeutic” concentration, 385
- prophylactic antibiotics, 385
- resistant bacteria, exposures, 385
- VRE, 385

objectives, 16

overuse/misuse, 379–381
- clinical decision support, 380
- vaccination, 380–381

prescriptions, importance, 14

URIs in children, 14

use in household cleaning products, 384
- antibacterial ingredients, 384
- bacterial contamination, 384
- triclosan, 384

Antifungal therapy, “golden age,” 128, 138

Antimicrobial agents, 1–23
- cell physiology and genetics, 7–10
- cellular physiologic mechanisms, 7
- chromosomal mutations, 8–9
- genetic basis for resistance, 7–8
- inducible mechanisms, 9–10
- measuring antimicrobial resistance, 10–12
- laboratory testing, 10–11
- surveillance, 11–12

See also Antimicrobial resistance

promoting factors/control measures, 12–23
- community-acquired pathogens, 12–16
- hospital-acquired pathogens, 16–23
- resistant pathogens, epidemiology of, 2–7
- antimicrobial resistance level, 2–6
- morbidity/mortality, implications for, 6–7

Antimicrobial resistance, 10–12
- laboratory testing, 10–11
- clinical resistance, 11
- micro organisms, isolation of, 10
- phenotype/genotype-based assays, 10
- *in vitro* chloroquine resistance, 11
- surveillance system, 11–12
- ABCs/EIP network, 12
- active or passive, 11
- definition, 11
- fluoroquinolone resistance, 12
- internal surveillance systems, 11
- macrolide resistance, 12

population-based surveillance, 12

VISA/VRSA infections, 12

Antimicrobial use, future trends, 379–386
- antibiotics
  - migration/lack of regulation, 382–384
  - overuse/misuse, 379–381
  - use in household cleaning products, 384
  - use in nonmedical settings, 384–386

See also Antibiotics

Antiretroviral drugs, classes, 337
- maraviroc (selzentry®), 337
- NRTIs/NNRTIs, 337
- raltegravir (isentress®), 337


Antivirals, 102, 117–120, 124–125, 293

ARIs, see Acute upper respiratory illnesses (ARIs)

Arthritis–dermatitis syndrome, 213

Aspartate aminotransferase (AST), 68–70, 257

Aspergillosis, 132–134
- diagnosis, 133
- ABPA, 133–134
- galactomannan, 133
- imaging studies, 134
- pathophysiology, 132–133
- taxonomic classification, 132
- treatment of, 143–145
- amphotericin B, 143
- combination antifungal therapy, 144–145
- echinocandins/posaconazole, 144
- voriconazole/itraconazole, 143

Aspergillus, 127, 140

AST, see Aspartate aminotransferase (AST)

Asymptomatic bacteriuria (ABU), 192–193

Asymptomatic/chronic carrier state, 192

Autoimmune diseases, 203, 295, 373

“Autoinoculation,” 339

Avian influenza, 111–114, 116, 112t

Azoles, 138–140
- fluconazole/voriconazole, 139
- itraconazole/posaconazole, 140

B

*Bacillus cereus*, 247
- diarrhea and emesis, cause, 247

Bacteria/fungi, differences, 128–129
Bacterial gastroenteritis, 240

*Campylobacter* species, 241

ETEC, 240

non-typhoidal *Salmonella enterica*, 242

Bacterial prophylaxis, 365

Bananas/rice/applesauce/toast (BRAT) diet, 236

Basic virology of influenza, 109–112

avian influenza viruses, 112

characteristics/pathogenicity, 112t

HPAI/OIE, 112

genetic changes

point mutation, 110

RNA segment reassortment, 110

host immune responses, 112

viral structure, 109

characteristics of influenza viruses, 110t

HA/NA glycoprotein, 109

influenza A/B/C, 109

RNA segments, 109

subtypes, influenza A viruses, 109

virulence features, 111

human virus subtypes H1/H2/H3, 111

mouse model, H1N1, 111

NS1 protein, 111

*B. catarrhalis*, 156

BDNA, *see* Branch chain DNA (bDNA)

Behcet’s syndrome, 197, 284

Beta-lactam antibiotics, 47–52

agents, 51

ampC gene, 51

antimicrobials, 48

aztreonam (monobactams), 48

BJM classification system, 48

carbapenem, 48

classification, 49t

ESBLs

detection (disk diffusion/E-test®), 50

non resistant combinations, 50

pinpoint mutations in genes, 48

production, 49–50, 50f

resistance to penicillins/cephalosporins/aztreonam, 50

extended-spectrum cephalosporins, 47

ceftazidime and ceferoime, 48

first/third/fourth-generation agents, 48

gram-negative spectrum, 47

amino group, 47

carboxypenicillin ticarcillin, 47

of penicillin G/piperacillin, 47

imipenem/meropenem/doripenem, 48

MBLs, *see* Metallo-beta-lactamases (MBLs)

non-beta-lactam agents, 52

oxyminocephalosporins, 49

penicillin agent subtypes/activity, 47t

Bites

clinical presentation

dog/cat bites, 309

infected bite wounds, complications, 309

edemiology, 309–310

microbiology

common pathogens, 310

treatment

antibiotic therapy for human/animal bites, 310

of human bites, antiretroviral agents, 311

BJM, *see* Bush, Jacoby, and Medeiros (BJM)

classification system

Blastomyces dermatitidis, 136–137

diagnosis, 137

epidemiology, 137

taxonomic classification, 136

Blastomycosis

treatment of, 146

Boils, *see* Furuncles/carbuncles

Brain

abscess, 242, 292

blood–brain barriers, 36, 289

Branch chain DNA (bDNA), 338

BRAT, *see* Bananas/rice/applesauce/toast (BRAT) diet

British Thoracic Society, 174

Bronchitis, acute

clinical description

asthma/allergic bronchospastic disorders, 162

cough, early indication of illness, 162

epidemiology, 162

etiology, 163

evaluation

bacterial infections, patients at high/low risk, 163

treatment

antibiotic treatment, 163

bronchodilators, use of, 164

Bullous impetigo, 304

Bush, Jacoby, and Medeiros (BJM)

classification system, 48–49, 49t, 51, 53–55, 57
CAB/F, see Catheter-associated bacteriuria/funguria (CAB/F)
Campylobacter, 241–242
  clinical presentation, 241
  etiology, 241
  treatment, 241–242
CA-MRSA, see Community-associated methicillin resistant Staphylococcus aureus (CA-MRSA)
CA-MRSA infection
  people at higher risk, 301
  TMP-SMX/tetracyclines, treating agents, 304
Cancer patients, 361–365
  fever in, 361
  immuno deficiencies/malignancies, 362–363
  CLL, 362
  hairy cell leukemia, 363
  Hodgkin’s lymphoma, 363
  MDS/LGLL, 363
  multiple myeloma, 362
  infection related to treatment, 364
    biliary tree/CVAD, 364
    cytotoxic chemotherapy, 364
    radiation therapy, 364
  location of malignancy, infections, 363–364
  management of infections, 364–365
    antimicrobial prophylaxis/therapy, 364–365
  catheter-related infections, 365
  myeloid growth factors/intravenous immunoglobulin, 365
Candida, 127, 140
Candidial infections, 129–132
  diagnosis, 132
  epidemiology, 129–130
    bloodstream infections/differences in, 130t–131t
    changing epidemiology, 130–131
    invasive candidiasis, risk, 131–132
    species commonly causing, 130t
  taxonomic classification, 129
Candidiasis, 231
  candidal esophagitis, 232
  factors, predisposition, 231
  oral candidiasis, 232
  thrush or oral candidiasis, 231
CAP, see Community-acquired pneumonia (CAP)
Carbuncles/furuncles
  clinical presentation
    erythematous, early indication, 305
    fever and malaise, symptoms, 306
    hot hand–foot syndrome, 305
    hot tub folliculitis, 305
  epidemiology
    risk factors, 306
    microbiology, 306
  treatment, 306
Catheter-associated bacteriuria/funguria (CAB/F), 191
Catheter-associated UTI (CAUTI), 191–192
  definition/presentation/epidemiology, 191
  bacterial (and fungal) colonization, 191
  CAB/F, 191
  prevention, 191
  antimicrobial-coated catheters, 191
  indwelling catheters, 191
  treatment, 192
CAUTI, see Catheter-associated UTI (CAUTI)
CD, see Crohn’s disease (CD)
CDAD, see C. difficile-associated diarrhea (CDAD)
CDC, see Centers for Disease Control (CDC)
CD4+ cells, 329, 331, 335, 337
C. difficile-associated diarrhea (CDAD), 248, 255
Cell physiology/genetics, antimicrobial resistance, 7–10
  cellular physiologic mechanisms, 7
    antibiotic permeability, 7
    bacterial porins, 7
    β-lactam-based antibiotics, 7
    chloroquine/tetracycline resistance, 7
  chromosomal mutations, 8–9
    co-resistances of microbial agents, 9
    gene cassettes, 9
    M. tuberculosis, 8
    plasmids/segments of genes, implications, 9
    short term resistant patterns, 8
  genetic basis for resistance, 7–8
    genetic alterations, types of, 7
    public health and clinical implications, 8t
    inducible mechanisms, 9–10
Cellulitis/erysipelas
  clinical presentation, 308
  epidemiology, 308
microbiology
beta-hemolytic (group A/B) *strept*, cause, 308
peri-orbital cellulitis, cause, 308
treatment, 309

Centers for Disease Control (CDC), 2–6,
12, 16, 19, 70–71, 75, 86, 116,
120–122, 195, 202, 205, 211,
213–215, 218, 223–227, 243, 246,
258, 290, 330, 333–335, 349, 359

Centers for Medicare and Medicaid Services
(CMS), 169, 175, 177, 355

Central nervous system (CNS) infections,
283–299
 acute encephalitis, 291–294
etiology, 291–292
laboratory diagnosis, 292–293
prognosis, 294
treatment, 293–294
 acute meningitis, 283–287
etiology, 283–284
laboratory diagnosis, 284–285
treatment of bacterial meningitis,
285–287
 chronic encephalitis, 294–297
etiology, 294–295
laboratory diagnosis, 296
prognosis, 297
treatment, 296–297
 space-occupying lesion syndrome,
297–298
diagnosis, 298
etiology, 298
treatment, 298
 subacute or chronic meningitis, 287–291
etiology, 287–288
laboratory diagnosis, 288
treatment, 289–291

Central venous access devices (CVAD),
364, 367

Cerebral spinal fluid (CSF), 34–35, 90, 135,
138, 205, 284–285, 288–292,
295–298

Cervarix (GlaxoSmithKline) vaccine, 208
Cervicitis, management of women with,
214–215
 clinical description, 214
MPC/PID, 214
epidemiology, 214–215
etiology, 215
treatment, 215

Chemoprophylaxis, 83–84
 oseltamivir/zanamivir, 83
 prophylactic antiviral therapy, assessment,
83–84

CHF, see Congestive heart failure (CHF)

Chlamydia pneumoniae, 152

Chronic lymphocytic leukemia (CLL), 362
bacterial pathogens, 362
enteric gram-negative organisms, 362
fungal/viral infections, 362
hypogammaglobulinemia, 362
purine analog therapy, pathogens, 362

Chronic peptic ulcer disease, 232
chronic gastritis, 232
endoscopic biopsy, 233
gastroesophageal endoscopy, 233
 Helicobacter pylori, 232
 symptoms, 233
urea breath test, 233

Cierny–Mader classification, 319–320
Clinical and Laboratory Standards Institute
(CLSI), 5t, 10, 49–50

Clinical features of influenza, 115–117
 avian subtypes, influenza A in humans,
116–117
 fatality rate, 117
incubation period, 116
multi-organ system failure, 116
seasonal influenza in adults, 115–116
 bacterial pathogens/pneumonia, 115
incubation period, 115
inhibition/transmission/replication, 114
pneumonia, primary or secondary, 115
postinfluenza asthenia, 115
risk factors, 115
symptoms/physical findings, 115
seasonal influenza in children, 116
childhood complications, 116
respiratory symptoms, 116

Clinical Laboratory Standards Institute (CLSI),
10, 49–50

Clinical pulmonary infection score (CPIS),
179–180, 179t

CLL, see Chronic lymphocytic leukemia
(CLLE)

Clorox®, undiluted household bleach, 333

Clostridium difficile, 247–249
 clinical presentation, 248
etiology, 248
 treatment, 249
 “donor stool,” surgery (total colectomy),
249
oral metronidazole, 249
probiotics/vancomycin, 249
Subject Index

CLSI, see Clinical and Laboratory Standards Institute (CLSI)
CMS, see Centers for Medicare and Medicaid Services (CMS)
CMV, see Cytomegalovirus virus (CMV)
CNS, see Central nervous system (CNS) infections
CNS immune reconstitution inflammatory syndrome (CNS-IRIS), 295, 297
CNS-IRIS, see CNS immune reconstitution inflammatory syndrome (CNS-IRIS)
Coccidial meningitis, 289
Coccidioides immitis/posadasii, 134–135
diagnosis, 135
epidemiology, 135
infection treatment, 145
ampicillin B deoxycholate, 145
fluconazole therapy, 145
posaconazole, 145
taxonomic classification, 134–135
Colonoscopy, 252
Common cold
clinical description, 151
epidemiology, 135
infection treatment, 145
ampicillin B deoxycholate, 145
fluconazole therapy, 145
posaconazole, 145
taxonomic classification, 134–135
CURB-65 scoring system, 174, 175t
Community-acquired bacterial meningitis, 285–286
adults, 285
asplenic patients, 286
infants and children, 285
neonates, 285
neutropenic patient, 286
Community-acquired methicillin resistant Staphylococcus aureus (CA-MRSA), 303
Community-acquired viral infections, 79–103
herpes simplex viruses, 86–94
influenza virus, 79–86
respiratory syncytial virus, 99–103
varicella zoster virus, 94–98
Community-associated methicillin resistant Staphylococcus aureus (CA-MRSA), 303
Congestive heart failure (CHF), 68t, 162, 274–275
Continuous quality improvement (CQI), 357
Coronaviruses, 152, 163
Coxackieviruses, see Herpangina
CQI, see Continuous quality improvement (CQI)
Craniofacial congenital abnormalities, see West Nile virus (WNV)
C-reactive protein (CRP), 224, 321, 348
Crohn’s disease (CD), 254–255
CRP, see C-reactive protein (CRP)
Cryptococcal meningitis, 289
Cryptococcus
epidemiology, 169–170
mortality rates, US, 170
penicillin, development of, 170
etiology, 170–171, 171f
bacteria, typical/atypical, 170
severity of illness, 171, 171t
management/treatment, 173–176
antimicrobial agent, selection, 175
clinical severity, 173–174
CURB-65 scoring system, 174, 175t
empiric treatment, recommendations, 175–176, 176t
first antibiotic dose, 175
IDSA/ATS guidelines, 175
major components, 173
PSI, scoring system, 174t
Cryptosporidium, 250–251
case-fatality rate, 171
cavitory lung findings, 172
chest radiographs, 172
clinical signs and symptoms, 172
 legionnaires, 172
physical examination, 172
pulse oximetry screening, 172
respiratory symptoms, 172
UAT, 173

Subject Index
CVAD, see Central venous access devices (CVAD)

Cystitis, 184–186
  definition/presentation/epidemiology, 184
  postmenopausal, 184
  risk factors, 184
  symptoms, 184
  diagnosis, 184–185
  patient-initiated therapy, 184
  positive dipstick or microscopy test, 184
  post-therapy testing, 184
  therapy, 185–186
  3-day therapy, 185
  single-dose fosfomycin, 186
  single-dose therapy, 185
  TMP–SMX (first-line agent), 185
  uncomplicated cystitis, 185t

Diarrhea, 236–237
  clinical presentation, 236
  treatment, 236–237

Direct immunofluorescence test (DFA), 197, 203

Directly observed therapy (DOT), 63–64, 66t, 70, 73

Directly observed therapy single session (DOT-SS), 196

Directly observed treatment-short course (DOTS), 70

Disseminated gonorrhea infection (DGI), 213

Disseminated gonorrhea infection (DGI), 213

Dysbiosis, 254

DRSP, see Drug-resistant S. pneumoniae (DRSP)

Drug-resistant S. pneumoniae (DRSP), 2, 12–13

Drug-resistant TB disease, treatment, 72–74
  anti-tuberculous drugs, 72
  drug resistance in patients, assessment, 72
  gastrointestinal side effects, 72
  long-term antibiotic therapy, 74
  potential regimens for management of, 73t
  re-treatment regimen, principles, 73–74
  second-line agents, 72
  cycloserine, 72
  Paser™ granules, 72
  pyridoxine, 72
  surgery indications, 74

Drug-susceptible TB disease, treatment, 63–72

DOT/combination antimicrobial preparations, 70–71
  advantages, 70
  DOTS, 70
  drug toxicity, 71
  epidemic control, 70
  fixed-dose combinations, 70
  general, 64–70
  AST level, 68–70
  clinical signs, 64
  culture-positive pulmonary TB, drug regimens, 65t–66t
  drug–drug interactions, 70
  first-line agents, 64
  gastrointestinal symptoms, 64
  INH/RIF/PZA/EMB, drugs, 64
  initial treatment, dosage recommendations, 67t
  local health department, 64
  pyridoxine/INH, 68
  treatment algorithm for tuberculosis, 69f
  tuberculosis, drugs, 68t
  patients co-infected with HIV, 71–72
  concurrent HIV infection, 71
  CYP450 enzymes, 71
  drug resistance, 71
  immunosuppression, 71
  paradoxical reaction or IRIS, 71–72
  rifamycins and drugs, interactions, 71
  TB–HIV co-infection, 71

DT104, see Definitive phage type 104 (DT104)

Dysbiosis, 254


Echinocandins, 128, 138, 141–145, 142t, 232, 368, 371

*E. coli* colitis, hemorrhagic, 238–240
  clinical presentation, 239
etiology, 239
treatment, 240
  antimotility drugs, 240
  intravenous rehydration, 240
  TMP–SMX/fluoroquinolones, 240
See also Hemolytic uremic syndrome (HUS)

*E. coli*, non-hemorrhagic, 240–241
  clinical presentation, 240
etiology, 240
treatment, 240–241

EEG, see Electroencephalogram (EEG)

EGWs, see External genital warts (EGWs)

*Eikenella corrodens*, 310

EIP, see Emerging Infections Programs (EIP) network

Electroencephalogram (EEG), 296

ELISA, see Enzyme-linked immunosorbent assay (ELISA) tests

EMB, see Ethambutol (EMB)

Emergency physician (EP), 355

Emerging Infections Programs (EIP) network, 12

Encephalitis
  acute, 291–294
  etiology, 291–292
  laboratory diagnosis, 292–293
  prognosis, 294
  treatment, 293–294
  chronic, 294–297
  antiretroviral drugs, characteristics, 297t
  etiology, 294–295
  laboratory diagnosis, 296
  prognosis, 297
  treatable/non-infectious causes, 296t
  treatment, 296–297

CMV, 293

Eastern equine, 294

HSV, 293

non-fatal, 294

VZV, 293

Endocarditis, 267–278
  antimicrobial therapy of resistant organisms, 273–276
  antibiotic prophylaxis, 275–276
  surgical therapy, 274–275
  clinical description, 267–270
  antimicrobial therapy, 272–273
  etiology, 270–272
  fungal endocarditis, 277–278
See also Infective endocarditis (IE)

*Entamoeba histolytica*, 250

*Enterococcus* species, 40–42
  broad-spectrum antibiotics, 40
  drug’s killing effect, 40
  *E. faecalis* and *E. faecium*, 40
  facultative anaerobic organisms, 40
  group D *streptococcus*, 40
  resistance to antibiotics, 40
  risk factors for VRE, 40–41
  susceptible to β-lactams, 40
  treatment, 41
    daptomycin, 41
    gentamicin or streptomycin, 42
    linezolid, 41
    quinupristin-dalfopristin, 41
    tigecycline, 41
    vanA gene cluster mechanism, 40
    vancomycin resistant, 40
    VRE/VSE infections, comparison, 41
See also Gram-positive bacteria, antimicrobial resistance

*Enterotoxigenic* *E. coli* (ETEC), 240

Enzyme-linked immunosorbent assay (ELISA) tests, 75, 128, 233, 250, 289, 331, 334

Enzyme reverse transcriptase, 335
  viral RNA into viral DNA, transcription, 335
  integrase/protease, 335

EP, see Emergency physician (EP)

Epidemiology, influenza, 113–115
  avian subtypes, 113–114
    H7N7/H7N3 subtype, 113
    HPAI H5N1, 113
  human infection and disease, 114t
    human-to-human transmission, 114
    subtype H9N2, 114
  pandemic/novel strains, 115
  seasonal influenza, 113
  factors affecting, 113
  influenza A/B, viruses/outbreaks, 113

Epididymitis, 216, 221

Epstein–Barr virus, see *Candidial infections*

Erythrocyte sedimentation rate (ESR), 224, 269

ESBLs, see Extended-spectrum β-lactamases (ESBLs)

*Escherichia coli*, 53–54
  aminopenicillins, 54
Subject Index

beta-lactam agents, 54
BJM functional group II, 53
efflux pumps or target-site modification, 54
ESBL-producing bacterium, 54
narrow-spectrum enzyme (TEM-1), 53
pinpoint mutations, 54
SMZ/TMP, 53
in UTIs, 53

ESR, see Erythrocyte sedimentation rate (ESR)
ETEC, see Enterotoxigenic E. coli (ETEC)
Ethambutol (EMB), 63, 66–68t, 73t, 290
Eustachian tube, 156–157
Exfolatin, see Staphylococcal scalded skin syndrome
Extended-spectrum β-lactamases (ESBLs), 3, 9, 48–51, 54–56
Extensively resistant tuberculosis (XDR-TB), 61–63
External genital warts (EGWs), 206–207

F
FDA, see Food and Drug Administration (FDA)
FE, see Fungal endocarditis (FE)
Federal Food, Drug, and Cosmetic Act, 383
Fetal varicella syndrome, 95, 98
Fluorescent treponemal antibody absorption (FTA-ABS), 203
Fluoroquinolones, 52
gram-negative activity, 52
ciprofloxacin and levofloxacin, 52
gemifloxacin and moxifloxacin, 52
multidrug efflux pumps, 52
mutational resistance, 52
Folliculitis
clinical presentation
erythematous, early indication, 306
hot hand–foot syndrome, 306
hot tub folliculitis, 306
epidemiology, 306
microbiology, 306
treatment
systemic antibiotic therapy, 307
warm compresses/topical antibiotics, use of, 306
Food and Drug Administration (FDA), 14, 57, 84, 91–92, 102, 222, 235, 273, 334
FTA-ABS, see Fluorescent treponemal antibody absorption (FTA-ABS)

Fungal endocarditis (FE), 277–278
antifungal agents, 278
antifungal therapy, 277
C. albicans azole resistance, 277
clinical features, 277
developmental factors, 277
echocardiography/blood cultures, 277
resistant fungal infections, 277
treatment, 277

Fungal meningitis, 287–288
Fungi, importance of, 128
Furuncles/carbuncles
clinical presentation
erythematous, early indication, 306
fever and malaise, symptoms, 306
hot hand–foot syndrome, 306
hot tub folliculitis, 306
epidemiology, 306
microbiology, 306

treatment, 306–307

G
Gardasil (Merck) vaccine, 208
GASP, see Gonococcal antimicrobial-susceptibility program (GASP)

Gastric infections (Helicobacter pylori), 232–235
clinical presentation, 233
etiology, 233
treatment, 234, 234t
lactic acid bacteria, 234
sequential therapy regimen, 234
triple therapy regimen, 234
See also Chronic peptic ulcer disease

Gastrointestinal (GI) tract, 366
infections, 231–262
acute infectious diarrhea, 236–237
Bacillus, 247
campylobacter, 241–242
Clostridium difficile, 247–249
cryptosporidium, 250–251
diverticulitis, 251–253
Entamoeba histolytica, 250
gastric infections (Helicobacter pylori), 232–235
hemorrhagic E. coli colitis, 238–240
hepatitis, 255–260
HPV/anal cancer, 253–254
inflammatory bowel disease, 254–255
intestinal infections, 235–236
Listeria, 247
non-hemorrhagic E. coli, 240–241
non-typhoidal Salmonella, 242–243
Gastrointestinal (cont.)
oral/esophageal (fungal) infections, 231–232
parasites, *Giardia*, 249–250
SBP, 260–262
*Shigella*, 244–245
traveler’s diarrhea, 237–238
typhoid fever, 243–244
*Vibrio cholerae*, 245–246
*Yersinia*, 246–247
Gay-related immune deficiency (GRID), 330
GBS, see Guillain-Barre Syndrome (GBS)
GC, see Gonococcal (GC) infections
Genital ulcer disease (GUD), 197–205
chancroid, 197–198
clinical description, 197
diagnosis, 198
epidemiology, 197–198
etiology, 198
treatment, 198, 198t
genital lesions
ulcerative/nonulcerative lesions, 197
HSV, 199–202
See also HSV in sexually transmitted diseases
syphilis, 202–205
See also Syphilis
Genito-urinary (GU) tract, 366, 372
Get Smart program, 16
GI, see Gastrointestinal (GI) tract
GISP, see Gonococcal Isolate Surveillance Project (GISP)
“Global Comparative Aspergillosis Study,” 143
Global pandemics, 79
Gonococcal antimicrobial-susceptibility program (GASP), 213
Gonococcal arthritis, 315–317
Gonococcal (GC) infections, 211
Gonococcal Isolate Surveillance Project (GISP), 213
Graft-versus-host disease (GVHD), 131, 369–370
Gram-negative bacteria, 45–58
aminoglycosides, 53
beta-lactam antibiotics, 47–52
characteristic features, 46
development pipeline, lack of agents, 58
examples of resistance mechanisms, 46t
fluoroquinolones, 52
gram-negative organisms, 53–57
*Acinetobacter baumannii*, 56–57
*Escherichia coli*, 53–54
*Klebsiella pneumoniae*, 54–55
*Pseudomonas aeruginosa*, 55–56
infections, primary care providers, 57–58
Gram-negative infections, primary care providers, 57–58
Gram-positive bacteria, antimicrobial resistance, 33–42
*Enterococcus* species, 40–42
MRSA, 37–39
community-associated, 38–39
healthcare-associated, 37–38
See also Methicillin-resistant *S. aureus* (MRSA)
*Staphylococcus aureus*, 36–37
*Streptococcus pneumoniae*, 33–36
VISA/VRSA, 39–40
definitions, 39
VRE, 40
GRID, see Gay-related immune deficiency (GRID)
Group A beta-hemolytic streptococcal tonsillopharyngitis
treatment of tonsillopharyngitis, use in, 160–161
“short-course” therapy with azithromycin, study, 161
Group A streptococcal carriers, 161
Group A streptococcus vaccine, 381
GU, see Genito-urinary (GU) tract
GUD, see Genital ulcer disease (GUD)
Guillain-Barre Syndrome (GBS), 82–83, 116, 122, 241
GVHD, see Graft-versus-host disease (GVHD)

H
HAART, see Highly active antiretroviral therapy (HAART)
HACCP, see Hazard Analysis and Critical Control Point (HACCP)
*Haemophilus influenzae*, 152
Hairy cell leukemia, 365
bacterial microorganisms, 365
T-lymphocyte dysfunction, 365
HAP, see Hospital-Acquired Pneumonia (HAP)
HAP and HCAP, 176–180
diagnosis, 178–179
epidemiology, 176–177
“community” infection, 177
definition, HAP, 177
HAP vs. CAP, advantage, 176
morbidity and mortality rates, 177
VAP, 177
etiology/prevention, 177–178, 178t
colonization of oropharynx, 177
colonizing bacteria, 177
ICU, 177
mechanical ventilation, 177
older ventilation systems, 177
treatment, 179–180
antimicrobial therapy, 179
broad-spectrum antimicrobials, 179
CPIS, 179–180, 180t
de-escalation of therapy, 179
empiric therapy, 179
multidrug-resistant bacteria, 179
VAP specific anti-biograms, 179
Hazard Analysis and Critical Control Point (HACCP), 385
HCAP, see Healthcare-Associated Pneumonia (HCAP)
Healthcare-associated pneumonia (HCAP), 169–170, 176–180
Healthcare Infection Control Practices Advisory Committee, 22
Hematopoietic stem cell transplants (HSCT), 369–371
Hemolytic uremic syndrome (HUS), 238
bloody diarrhea/abdominal pain, 239
complications/mortality rate, 239
incubation period, 239
Shiga-toxin-producing E. coli strain, 239
Hepatitis, 255–260
hepatitis A, 255–256
antibody testing, 256
clinical presentation, 256
etiology, 256
hepatitis A virus (HAV), 256
pre-icteric and icteric phases, 256
treatment, 256
hepatitis B, 256–258
clinical presentation, 257
etiology, 257
HBV infection, markers, 257
hepatitis B virus (HBV), 257
treatment, 258
hepatitis C, 258–260
clinical presentation, 258–259
etiology, 259
hepatitis C virus (HCV), 258
treatment, 259–260
hepatitis D, 260
virus (HDV), 260
hepatitis E, 260
virus (HEV), 260
Hepatocellular carcinoma, 257–258
“Herd immunity,” 82
Herpangina, 88
Herpes simplex viruses (HSV), community-acquired viral infections, 86–94
clinical syndromes, 87–91
CNS infections, 90
HIV/HSV, 89–90
HSV in pregnancy, 90–91
keratoconjunctivitis, 89
mucocutaneous infection, 87–88
neonatal disease, 89
pregnancy, 92–93
antiviral medications, 92
primary infection, treatment, 93
recurrent infection, treatment, 93
resistance in immunocompromised patients, 93–94
acyclovir-resistant HSV infection, 93
antiviral-susceptibility testing, 93
cidofovir, 93–94
first-line therapy (foscarnet), 93
valacyclovir/famciclovir, cross resistance, 93
treatment, 91–92
famciclovir, 91
doing genital HSV infections, 92t
virology, 86–87
double-stranded DNA viruses, 86
HSV II infection, serologic evidence, 87, 87t
HSV I infections, factors influencing, 86–87
primary and recurrent infections, 86
risk of transmission, 87
Herpes zoster, 95
CNS syndromes caused by VZV, 95
immunocompromised host, 95
ophthalmic branch complications, 95
postherpetic neuralgia, 95
unilateral vesicular rash, 95
zoster oticus, 95
Hib, see H. influenzae type b (Hib) vaccine
HICPAC, see Hospital Infection Control Practices Advisory Committee (HICPAC)
Highly active antiretroviral therapy (HAART), 288, 295, 297
Highly pathogenic avian influenza (HPAI), 112–114, 112t, 117
High-resolution computed tomography scan (HRCT), 134
H. influenzae B vaccine, 156
H. influenzae type b (Hib) vaccine, 381
Histoplasma capsulatum, 136
diagnosis, 136
epidemiology, 136
taxonomic classification, 136
Histoplasmosis
treatment of, 146
HIV, see Human immunodeficiency virus (HIV)
HIV/AIDS, 329–341
clinical course, 330–331
CD4+ cells, 331
constitutional symptoms, 330
viral replication, 331
“window period,” 330
diagnosis, 334
HIV ELISA test, 334
HIV screening, 334
OraQuick Advance® , 334
Western blot assay, 334
epidemiology, 331–332
“AIDS-defining illnesses,” 331, 331t
AIDS rates, US, 332
ELISA tests, 331
“HIV” or an “AIDS” category, 331
“HIV positive (HIV+)”, 331
Western blot, 331
pathogenesis, 334–336
Bactrim DS®, prophylactic regimen, 335
CD4+ cells, HIV infection, 335
CXCR4 co-receptor, 335
enzyme reverse transcriptase, 335
HIV-1/HIV-2, comparison, 334–335
HIV replication cycle, 336f
opportunistic infections (OIs), 335
pharmacotherapeutics, 337–340
antiretroviral drugs, classes, 337
antiretroviral monotherapy, 338
“autoinoculation,” 339
combination antiretroviral product, examples, 339
drug interactions, management, 339
medication or disease-related adverse effects, 337
multi-drug regimen, 338
“salvage therapy,” 338
viral enzymes, 339
viral load testing, 338
resistance testing, 340–341
antiretroviral resistance testing, 340
genotypic and phenotypic resistance assays, comparison, 340t
transmission, 332–334
drug selection, 334
Injection drug users (IDUs), 333
intrauterine transmission, HIV, 332
maternal–child transmissions, 333
“opt-out” strategy, 333
PEP regimen, 333
perinatal transmission, 332
reverse transcriptase inhibitor-based regimen, 333
sexual contact, 332
three-drug regimen, 333
HIV/AIDS, infection, 372
etiologic agents, 372
immuno deficiencies, 372
treatment, 372
Quantiferon test/TST, 374
“HIV positive (HIV+)”, 205, 227, 232, 331, 373
HIV–TB co-infection, 61
H1N1 influenza virus, 86
Hodgkin’s lymphoma, 363
combined-modality therapy or relapse, 363
encapsulated organisms, 363
laparotomy/splenectomy, 363
Hospital-acquired pneumonia (HAP), 176–180
Hospital Infection Control Practices Advisory Committee (HICPAC), 274
Hot hand–foot syndrome, 305
Hot tub folliculitis
fluoroquinolones/cephalosporins, treatment of, 306
HPAI, see Highly pathogenic avian influenza (HPAI)
HPV/anal cancer, 253–254
phase III trials, 253
risk factors, 253
squamous cell carcinoma, 253
HRCT, see High-resolution computed tomography scan (HRCT)
HSCT, see Hematopoietic stem cell transplants (HSCT)
HSCT recipients, infections in etiologic agents, 367
bacterial sinopulmonary infections, 367
post-transplant infections, 370
immuno deficiencies, 368
prophylaxis/treatment, 368
anti-mold prophylaxis, 368
Aspergillus guidelines, 368
drug resistant organisms, 368
Pneumocystis prophylaxis, 368
prophylactic/preemptive ganciclovir therapy, 368
HSV in sexually transmitted diseases, 199–202
  clinical description, 199
  antigenic types (HSV-1/HSV-2), 199
  genital HSV, 199
  infection/symptoms, 199
  primary genital herpes, 199
  serologic testing, 199
  type-specific IgG testing, 199
  treatment, 200–202
    acyclovir resistance, 201
    antiviral therapy, 200, 202
    cidofovir/foscarnet/trifluridine, 201
    episodic/suppressive therapy, 200
    of genital herpes in persons infected
    with HIV, 200t
    of HSV infection, 200t
    pharmacotherapy, 200
  transmission/prevention, 201
Human immunodeficiency virus (HIV), 6,
  36, 62, 64, 66, 68, 71–76, 89–98,
  122–123, 131, 138, 195–198,
  200–206, 211, 218, 221–222, 224,
  227, 232, 251, 253, 259, 284, 287,
  290–293, 295–298, 310–311, 321t,
  329–342, 361, 373–374
  and HSV, 89–90
  HIV-1 seropositive individuals, 89
  infections, 90
Human papilloma virus (HPV), 206–208
  clinical description, 206
  biopsy/acetowhite test, 206
  EGWs, 206
  squamous intraepithelial
  lesions, 206
diagnosis, 206
  instrumentation (colposcopy/
anoscopy/urethroscope), 206
  speculum examination, 206
epidemiology, 206
etiology, 206–207
treatment, 207–208
cryotherapy, 207
  of genital warts*, 208t
  patient-applied/provider-administered
  therapies, 207
  podoflox/podophyllin, antimiotic
  agents, 207
  prophylactic HPV vaccines,
  207
  surgeries/injections, 207
HUS, see Hemolytic uremic syndrome
  (HUS)
Hypogammaglobulinemia, 362, 365

I
IBD, see Inflammatory bowel disease (IBD)
ICU, see Intensive care unit (ICU)
IDSA, see Infectious Diseases Society of
  America (IDSA)
IDUs, see Injection drug users (IDUs)
IFI, see Invasive fungal infections (IFI)
Immu reconstitution inflammatory syndrome
  (IRIS), 71–72, 288, 295, 297
Immunocompromised host, infections in,
  361–374
cancer patient, 364–365
HIV/AIDS, 374
HSCT recipient, 367–368
neutropenic patient, 365–366
SOT recipient, 368–371
TNF-α inhibitors, 373–374
Immunomodulation therapy, 381
Impetigo
  clinical presentation
    bullous/nonbullous impetigo, 304
  epidemiology, 304
  microbiology, 304
  treatment
    oral antibiotics recommended, 305
    topical antibiotics, use of, 305
    topical mupirocin, use of, 305
Infectious Diseases Society of America
  (IDSA), 23, 58, 175,
  365–366, 368
Infective endocarditis (IE), 267
  antibiotic prophylaxis, see Antibiotic
  prophylaxis, endocarditis
  antimicrobial therapy, 272–274
  acute infective endocarditis, 272
  combined therapy, 272
  empiric antibiotic therapy, 272
  treatment of SBE, 272t–273t
clinical description, 267, 270
  AHA guidelines, 270
  bacteremia, 270
  cardiac complications, 268
  clinical presentations, 268
  diagnosis, Duke’s clinical criteria, 269t
  echocardiographic findings, 270
  laboratory abnormalities, 269
  left-sided/right-sided IE, 267
  neurological symptoms, 268
  non specific symptoms, 268
  Osler’s nodes, 268
  right-sided valvular complications, 268
  risk factors, 267
  TEE/TTE, 270
Infective endocarditis (cont.)
etiology, 270–272
  bacterial/uncommon pathogens, 270
gram-negative bacteria, 270–271
  HACEK organisms, 270
MRSA, 271
  predominant/isolated pathogens, 271
PVE and mortality rates, 271
VRE infections, 272
FE, see Fungal endocarditis (FE)
resistant organisms, antimicrobial therapy, 273–274
daptomycin, 273
  enterococci/enterococcal infections, 274
tigecycline, 273–274
vancomycin use, 273–274
surgical therapy, 274–275
cardiopulmonary instability, 275
CHF, 274
  perivalvular extension, 275
  progressive glomerulonephritis, 275
valve replacement surgery, 275
INF-γ, see Interferon-γ (INF-γ)
Inflammatory bowel disease (IBD), 254–255
etiology, 254
  NOD2/CARD15 gene defect, 254
treatment, 254–255
  CD/UC, 255
  colonic disease vs. ileal disease, 255
metronidazole/ciprofloxacin, 254
  pouchitis, 255
rifaximin, 254
Influenza, 109–125
basic virology, 109–112
  avian influenza viruses, 112
  genetic changes, 110–111
  host immune responses, 112
  viral structure, 109
virulence features, 111
See also Basic virology of influenza
clinical features, 115–117
  avian subtypes of influenza A in humans, 116–117
  seasonal influenza in adults/children, 116
See also Clinical features of influenza
diagnosis, 117
  bronchoalveolar lavage, 117
  immunofluorescence or enzyme immunosassays, 117
  polymerase chain reaction-based assays, 117
sporadic cases of influenza, 117
epidemiology, 112–115
  avian subtypes, 113–114
  pandemic/novel strains, 114
seasonal influenza, 112
prevention, 121–125
  antiviral prophylaxis, 124–125
  vaccination in adults, 121–122
  vaccination in children, 123–124
vacine basics, 121
treatment with antivirals, 117–119
  adamantanes, 118
  antiviral resistance, 120
  neuroaminidase inhibitors, 119–120
Influenza A or B virus, 152
Influenza vaccine, 81–83
  antibody titers/antigenic variation, 83
dosing recommendations, 83t
effectiveness of, 82t
“herd immunity,” 82
influenza A strains/B strain, 81
  recommendations, 82
side effects, 82–83
Influenza virus, 79–86
antiviral resistance, 86
clinical syndromes, 80–81
  cervical adenopathy, 80
  characteristics/symptoms of infection, 80
  myositis and rhabdomyolysis, 81
  primary influenza pneumonia, 80
  risk factors, 80
  secondary bacterial pneumonia, 80
diagnosis, 81
epidemiology, 80
prevention, 81–84
  chemoprophylaxis, 83–84
  vaccine, see Influenza vaccine
treatment, 84–86
  adamantanes, 85–86
  neuraminidase inhibitors, 84
virology, 79–80
  antigenic shift/drift, 79
  infection or vaccination, 79
  influenza A virus, 79
  orthomyxovirus family, 79
Injection drug users (IDUs), 87, 89, 332–333
Intensive care unit (ICU), 5t, 22, 55, 131, 171, 174, 177, 294, 349, 352
Interferon-γ (INF-γ), 74–75
International Union Against Tuberculosis and Lung Disease, 6
Intestinal infections (viral infections), 235–236
norovirus, 235–236
rotavirus, 235
Intravenous drug abusers (IVDAs), 267,
271–272, 277, 301
Intravenous immunoglobulin (IVIG), 98, 249, 365
Invasive candidiasis, treatment of, 141–143
amphotericin B/candidiasis, 142
echinocandins/candidiasis, 142–143
fluconazole, 142
Invasive fungal infections (IFI), 127–146
aspergillosis, 132–134
diagnosis, 133
pathophysiology, 132–133
taxonomic classification, 132
bacteria/fungi, differences between, 128–129
blastomyces dermatitidis, 136–137
diagnosis, 137
epidemiology, 137
taxonomic classification, 136
candidial infections, 129–132
diagnosis, 132
epidemiology, 129–130
taxonomic classification, 129
Coccidioides immitis/posadasii, 134–135
diagnosis, 135
epidemiology, 134–135
taxonomic classification, 135
cryptococcus neoformans, 137–138
diagnosis, 138
epidemiology, 137–138
taxonomic classification, 137
fungi, importance of, 128
histoplasma capsulatum, 136
diagnosis, 136
epidemiology, 136
taxonomic classification, 136
treatment strategies/options, 138–146
aspergillosis, 143–145
azoles, 138–140
blastomycosis, 146
coccidioidal infection, 145
cryptococcus infection, 146
echinocandins, 141
histoplasmosis, 146
invasive candidiasis, 141–143
polyene antifungals, 140–141
IRIS, see Immune reconstitution inflammatory syndrome (IRIS)
IVDAs, see Intravenous drug abusers (IVDAs)
IVIG, see Intravenous immunoglobulin (IVIG)
J
Jarisch–Herxheimer reaction, 204–205
K
Kaposi’s sarcoma, 331, 335, 372
keratoconjunctivitis, 89
corneal opacification, 89
recurrent viral shedding, 89
superficial or deep structures, infections of, 89
Klebsiella pneumoniae, 54–55
beta-lactamase inhibitor, 55
community-acquired pneumonia, 54
efflux pumps/NNIS system, 55
extended-spectrum cephalosporins, 55
harbor resistance mechanisms, 54
hospital-acquired/ventilator-associated pneumonia, 54
multidrug resistance, 55
mutation of DNA gyrase, 55
oxyiminocephalosporins, 55
SHV-1 (BJM class IIB), 54
topoisoerasme IV mutation, 55
Klebsiella pneumoniae carbapenemase (KPCs), 49t, 51–52
KPCs, see Klebsiella pneumoniae carbapenemase (KPCs)
L
LAIV, see Live attenuated virus (LAIV)
Large granular lymphocytic leukemia (LGLL), 366
Latent tuberculosis infection (LTBI), 61, 74–75
LCR, see Ligase chain reaction (LCR)
LGLL, see Large granular lymphocytic leukemia (LGLL)
LVG, see Lymphogranuloma venereum (LGV)
Ligase chain reaction (LCR), 210
Listeria, 247, 284, 363, 373–374
Live attenuated virus (LAIV), 121–122, 124
LTBI, see Latent tuberculosis infection (LTBI)
Lyme disease, 287, 291
Borrelia burgdorferi, 287
disease manifestation/characteristics, 287
Lymphogranuloma venereum (LGV), 197, 205, 210, 216
M
MAC, see Mycobacterium avium complex (MAC)
MBLs, see Metallo-beta-lactamases (MBLs)
MDR, see Multidrug-resistant (MDR) bacteria
MDR-TB, see Multidrug-resistant tuberculosis (MDR-TB)
MDS, see Myelodysplastic syndrome (MDS)
Meningitis, 289–290
  acute, 283–287
  etiology, 283–284
  laboratory diagnosis, 288
  treatment of bacterial meningitis, 285–287
bacterial, 285–287
  Haemophilus influenzae (children), 284
  Streptococcus pneumoniae (adults), 284
  coccidial, treatment of, 289
cryptococcal, treatment of, 289–290
  fungal, 287–288
  Cryptococcus neoformans, 287
  granulocytopenia, risk factors, 287
lyme disease
  AAN practice guidelines, 291t
  treatment of, 291
meningococcal, 285
  meningococcal, 283
  neonatal, 284
  Listeria monocytogenes, 284
neurosyphilis
  treatment of, 290–291
subacute or chronic, 287–291
  etiology, 287–288
  laboratory diagnosis, 288
tuberculous
  treatment of, 289–291
viral
  enteroviruses/arboviruses, 284
Meningococcal meningitis, 283
Metallo-beta-lactamases (MBLs), 51
  “carbapenemases,” 51
  ESBL-producing K. pneumoniae, 52
  KPCs, 51–52
  Stenotrophomonas maltophilia, 51
Methicillin-resistant S. aureus (MRSA), 22, 271, 318
  community-associated, 38–39
  CA-MRSA infections, 39
  daptomycin, 39
  linezolid, 39
  MRSA infections, 38
  SCCmec IV/V, 38
  SSTIs, 38
  treatment, 39
tygecycline, 39
vancomycin therapy, 39
healthcare-associated, 37–38
  device-associated infections, 37
  hospital-acquired infections, 37
  risk factors, 37

S. aureus bacteremia/MRSA,
  comparison, 38
  nosocomial pneumonia, 39
Methicillin-susceptible S. aureus (MSSA), 38–39, 318
MHA-TP, see Microhemagglutination assay for T. pallidum antibody (MHA-TP)
Microhemagglutination assay for T. pallidum antibody (MHA-TP), 203
MICS, see Minimum inhibitory concentrations (MICs)
Minimum inhibitory concentrations (MICs), 10, 41, 50, 214
MM, see Multiple myeloma (MM)
Mollaret’s meningitis, 284
MPC, see Mucopurulent cervicitis (MPC)
MRSA, see Methicillin-resistant S. aureus (MRSA)
MSSA, see Methicillin-susceptible S. aureus (MSSA)
Mucocutaneous infection, 87–88
  chemotherapy or radiation therapy, 88
  genital herpes (HSV), 88
  HSV exposure, 87
  primary HSV II genital infection, symptoms, 88
  recurrent infections, 88
  neurologic/systemic complications, 88
  prodrome, 88
  symptoms in childrens/adults, 88
Mucopurulent cervicitis (MPC), 214
Multidrug-resistant (MDR) bacteria, 3t, 46–47, 52, 55, 57, 61–63, 71, 73–76
Multidrug-resistant tuberculosis (MDR-TB), 2, 6, 8, 61–63, 74–76, 382
Multiple myeloma (MM), 362
  encapsulated organisms, 363
  humoral immune defects, 362
  impaired humoral immunity, 362
Mycobacterium avium complex (MAC), 321t, 335, 372
Mycoplasma pneumoniae, 152
Myelodysplastic syndrome (MDS), 363
Myeloma, 362, 365
Myelosuppressive chemotherapy, 365

N
NAATs, see Nucleic acid amplified tests (NAATs)
National Ambulatory Medical Care Survey, 16
National Comprehensive Cancer Network (NCCN), 365, 368
National Guideline Clearinghouse, 354
Subject Index

National Jewish Medical and Research Center, 63

National Nosocomial Infections Surveillance System (NNIS), 54–55, 130

NCCN, see National Comprehensive Cancer Network (NCCN)

Neonatal HSV infection, 89
  inoculation of newborns, 89
  neonatal HSV/disseminated infections, 89
  primary maternal infection, 89
  vertical transmissions, 89

Neuraminidase inhibitors, 84, 117
  oseltamivir, 84
  treatment/effects, 84
  zanamivir, 84
  treatment/effects, 84

Neutropenia, 363, 366, 368
  etiologic agents, 369–371
  bacterial infections, 369
  fluconazole prophylaxis, 368
  fungal infections, 370
  sources of
    ANC, infection risk, 365
    myeloablative therapy, 365
    single oral temperature, 365
  treatment, 371

N. gonorrhoeae resistant to fluoroquinolones (QRNG), 213–214

NGU, see Nongonococcal urethritis (NGU)

NNIS, see National Nosocomial Infections Surveillance System (NNIS)

NNRTIs, see Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

Nonbullous impetigo, 304
  “Non-culture” method, 132–133

Nongonococcal urethritis (NGU), 211–212

Non-group A streptococcal pharyngitis, 161

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), 337

Non-steroidal anti-inflammatory (NSAID) use, 252, 284

NRTIs, see Nucleoside reverse transcriptase inhibitors (NRTIs)

NSAID, see Non-steroidal anti-inflammatory (NSAID) use

Nucleic acid amplified tests (NAATs), 209–210, 212

Nucleoside reverse transcriptase inhibitors (NRTIs), 5t, 333, 337–338

O

OIE, see Organization for Animal Health (OIE)

OIs, see Opportunistic infections (OIs)

Opportunistic infections (OIs), 295, 329, 335, 339, 372

Optimal antimicrobial use, strategies for
  antibiotic control policies
    administrative interventions, 351–352
    antibiotic control programs/team experts, aim, 350
    antibiotic use in different units of hospital, impact, 351
    basic hospital infection control practices, promotion, 350
    pharmacists/infection control teams, role of, 350
    antibiotic resistance/volume of consumption, proportionality, 347
  audit and feedback
    Cochrane review for antibiotic use in otitis media, 356

clinical guidelines
  CAP guidelines, study, 355
  community-acquired pneumonia, management of, 354
  National Guideline Clearinghouse, 354
  practice guidelines, definition, 354
  selection of ‘champions’ (physicians/nurses), 354
  for treatment of uncomplicated cystitis, 355
  use in educational efforts, advantages, 355

computer-assisted decision support
  advantages, 352
  antibiotic costs, impact on, 352
  PDA clinical decision support system, role, 352

controlling antibiotic prescribing, goal, 347–349

diagnostic certainty improvement, clinical guidelines, 348

overuse of antibiotics, contributing factors, 348t

procalcitonin-guided therapy, 348

viral/bacterial infection assessment, strategies, 348

delayed prescriptions
  avoiding antibiotics, reasons/consequences, 357
  disadvantages, 357

multifaceted interventions
  CQI initiatives, 357
  treatment of uncomplicated acute bronchitis in adults, study, 357–358
Optimal antimicrobial (cont.)
‘post-antimicrobial era,’ concern, 347–348
provider education
   educational methods on antibiotic
   prescribing, effects, 353
   educational outreach visits/academic
   detailing, techniques/advantages, 353
   interactive educational meetings,
effectiveness, 353
quality improvement initiatives
   antibiotic use in outpatient/inpatient
   settings, strategies, 350
   educational outreach visits, 350
   multifaceted interventions, 350
   peer education, 350
   point-of-care delivery, impact, 350
   single age groups, impact on, 349
   strategies to promote optimal
   antimicrobial use, 351t
   traditional teaching methods,
effectiveness, 349
Oral/esophageal (fungal) infections, 231–232
   clinical presentation, 231–232
   treatment, 232
      ketoconazole/fluconazole/itraconazole,
      232
      nystatin/clotrimazole, 232
See also Candidiasis
Oral rehydration treatment (ORT), 236
Organization for Animal Health (OIE), 112
ORT, see Oral rehydration treatment (ORT)
Osteomyelitis in adults, 319–325
   Cierny–Mader staging system, 320t
diagnosis, 321–322
      chronic osteomyelitis, 321
      CRP, sensitivity, 321
      imaging studies, 321–322
      microbiologic diagnosis, 322
      selected imaging studies, indications/limitations, 323t
etiology, 320–321
   bacterial osteomyelitis, microorganisms
   with, 321t
   contiguous-focus osteomyelitis, 320
   hematogenous osteomyelitis, 320
   posttraumatic osteomyelitis, 320
   vertebral osteomyelitis, 320
   treatment, 322–325
      antimicrobial management, 323–325,
      324t–325t
      major debridement surgery, 324
      oral therapy, 325
   “paprika” sign, 322
   PICC line, 325
   surgical management, 322
   therapy of osteomyelitis, 322
Otitis media, acute
diagnosis, essential components for
   acute onset of illness, 155
   presence of middle ear effusion, 155
   signs/symptoms of middle ear
   inflammation, 155
epidemiology
   H. influenzae B vaccine, use of, 156
   predominant in males/younger children, 156
etiology
   Eustachian tube dysfunction, impact,
   156
   otitis media, causes, 157
   suppurative otitis media, cause, 156
treatment
   antibiotic therapy, recommendations,
   157
   intramuscular dose therapy of
   ceftriaxone, 157
   WASP approach, 157
   treatment failures, management of
   broad/narrow-spectrum antibiotics, use
   of, 158
P
P.-aminosalicylic acid (PAS), 63, 68t, 72–73, 73t
Panton Valentine leukocidin (PVL) gene, 381
   “Paradoxical reaction,” 71–72
Parasites, Giardia, 249–250
   clinical presentation, 249–250
etiology, 250
   treatment, 250
PAS, see P.-aminosalicylic acid (PAS)
Pathogens
   community-acquired, 12–16
      antibiotic, see Antibiotics
      antimicrobial exposure, 12–13
      combination tools, 13
      day care attendance, 13
      new drug development, 14
      “prescription pads,” 16–17, 17f
      S. pneumoniae, 13
      types/implications for control measures,
      13t
      vaccines, 13
      gram-negative, 45–46
      hospital-acquired, 16–23
antimicrobial stewardship, 23
control of resistance, measures, 22
extended-spectrum β-lactam antibiotics, 22
face-to-face educational interventions, 23
*K. pneumoniae*, 22
nosocomial pathogens, 16
preventing transmission, guidelines, 22
ventilator-associated pneumonia, 23
VRE/MRSA, 22

PBPs, *see* Penicillin binding proteins (PBPs)

PCP, *see* Pneumocystis jiroveci pneumonia (PCP)

PCR, *see* Polymerase chain reaction (PCR)

PCR-based testing, 81

PDA, *see* Personal digital assistant (PDA)

Pelvic inflammatory disease (PID), 214, 223–226
clinical description, 223–224
diagnosis, 224
treatment, 224–226, 225

Penicillinase-producing *N. gonorrhoeae* (PPNG), 211, 213

Penicillin binding proteins (PBPs), 7, 34, 213

PEP, *see* Post-exposure prophylaxis (PEP)

Peptide nucleic acid fluorescent in situ hybridization (PNA-FISH), 128

Periorbital cellulitis, 308

Peripherally inserted central catheter (PICC line), 325

Peritonitis, spontaneous, 260–262

Personal digital assistant (PDA), 352

Pharyngitis, sexually transmitted, 215
gonococcal/gonorrhea pharyngitis, 215

PICC line, *see* Peripherally inserted central catheter (PICC line)

PID, *see* Pelvic inflammatory disease (PID)

Pinpoint mutations in genes, 48, 54

PLs, *see* Protease inhibitors (PIs)

“Plaster mold,” 129

PML, *see* Progressive multifocal leukoencephalopathy (PML)

PMNL, *see* Polymorphonuclear leukocyte (PMNL) count

PNA-FISH, *see* Peptide nucleic acid fluorescent in situ hybridization (PNA-FISH)

Pneumocystis jiroveci pneumonia (PCP), 329, 331, 335

Pneumonia, 169–180
diagnosis/tests, 172–173

epidemiology, 169
etiology, 170–171
management/treatment, 173–176

See also Community-acquired pneumonia (CAP)

HAP/HCAP, 176–180
diagnosis, 178
epidemiology, 176–177
etiology/prevention, 177–178
treatment, 179–180

See also HAP and HCAP

Pneumonia severity index (PSI), scoring system, 174

Polyene antifungals, 140–141
amphotericin B, 141

Polymerase chain reaction (PCR), 81, 96, 101, 128, 152, 197, 199, 203, 210, 248, 259–260, 288, 296, 298, 338, 368

Polymorphonuclear leukocyte (PMNL) count, 261

Posaconazole, 127–128, 139–140, 144–145, 278, 368

Post-exposure prophylaxis (PEP), 97–98, 293, 333–334

IVIG, 98

V ariZIG, 97–98

VZIG, 97

PPI’s, *see* Proton pump inhibitors (PPI’s)

PPNG, *see* Penicillinase-producing *N. gonorrhoeae* (PPNG)

Pregnancy, HSV in, 90–91
maternal–fetal transmission, 90
rate of, 91
risk factors, 90
vertical transmission/pregnancy-related morbidity, 90

Prevention of influenza, 121–125
antiviral prophylaxis, 124–125
adamtanes, 124
oseltamivir and zanamivir, 124
pandemic influenza, 125
vaccination in adults, 121–123
antivirals for treatment/prophylaxis, 118
mortality reduction, 122
risk groups, age, 122
targeted groups for influenza vaccination, 123
TIV-LAIV comparative trial, 122
candidate efficacy, 121
vaccine efficacy, 121
drug and dosage administration, 124
febrile illness, 122
Prevention of influenza (cont.)
laboratory-confirmed influenza, 123
LAIV vs. TIV efficacy rates, advantage, 123
side effects, 122
vaccine basics, 121
antigenic drift/shift, 121
human strains, influenza A/B, 121
inactivated compound (TIV), 121
live attenuated virus (LAIV), 121
vaccine manufacture, 121
WHO/CDC, 121

Procalcitonin-guided therapy, 348
Proctitis/proctocolitis/enteritis, sexually transmitted, 216
clinical description, 216
diagnosis, 216
treatment, 216
Progressive multifocal leukoencephalopathy (PML), 295–298, 331t
Prosthetic valve endocarditis (PVE), 270–272, 275
Protease inhibitors (PIs), 330, 337
Proton pump inhibitors (PPI’s), 233, 237
*Pseudomonas aeruginosa*, 55–56, 306
antimicrobial efflux pumps, 56
BJM class I, 55–56
class II (ESBLs)/class III (carbapenemases), 56
hospital-acquired infections, 55
imipenem/carbapenem resistance, 55
monotherapy, 56
mutational resistance, 55
OprD, downregulation, 56
tigecycline, 55
PSI, see Pneumonia severity index (PSI), scoring system
Pulse oximetry screening, 100, 172
PVE, see Prosthetic valve endocarditis (PVE)
PVL, see Panton Valentine leukocidin (PVL)
gene
Pyelonephritis, 186–189
definition/presentation/epidemiology, 186
diagnosis, 186–187
CT or ultrasonography, 186–187
pre-therapy urine culture, 186
pyelonephritis, 186
pyuria or bacteriuria, 186
therapy, 187–189
antibiotic therapy, 189
empirc therapy, 187
fluoroquinolones, 189
intravenous therapy, 187
levofloxacin, 189
non-fluoroquinolone based therapy, 189
resistant uropathogens, 189
uncomplicated pyelonephritis, 188t

Q
QRDR, see Quinolone Resistance Determining Region (QRDR)
QRNG, see *N. gonorrhoeae* resistant to fluoroquinolones (QRNG)
Quinolone Resistance Determining Region (QRDR), 213

R
Ramsey Hunt Syndrome, 95
Rapid plasma reagin (RPR), 203
Recurrent UTI, 190–191
definition/epidemiology, 190
prevention, 190–191
antimicrobial therapy, 190
topical estrogen therapy, 190
Reiter’s syndrome, 197
Resistant pathogens, epidemiology of, 2–7
level of antimicrobial resistance, 2–6
antimicrobial therapy, 2
chloroquine-resistant malaria, 2
*Mycobacterium tuberculosis* strains, 6
parasitic resistance, 2
public health burden, 2–5, 3t–5t
morbidity/mortality, implications for, 6–7
drug resistance, 7
meflocholin-resistant/susceptible, mortality rates, 6
multidrug-resistant HIV, 6
public health threats, 2
amantadine/rimantadine resistant, 2
meplocholin-resistant (*Staphylococcus aureus*), 2
multidrug-resistant tuberculosis, 2
oseltamivir-resistant (influenza virus), 2
vancomycin-resistant (*Enterococcus*), 2
Respiratory syncytial virus, 99–103
childhood infection, 101
bronchiolitis or pneumonia, 101
signs and symptoms, 101
diagnosis, 101
disease pathogenesis, 99–100
infection in adults and elders, 101
symptoms, 101
trapeobronchitis, 101
infection in infants, 100
apnea, 100
clinical/laboratory findings, 100
complications/recurrences, 100
neonatal infection, 100
prevention, 102–103
  infection control guidelines, 102–103, 103t
palivizumab, 102
treatment, 101–102
  bronchodilators/anti-inflammatory agents, 101–102
ribavirin therapy, 102
virology and epidemiology, 99
  infectious sources/transmission, 99
  lower respiratory-tract infections, 99
  re-infection rates, 99
  risk factors, 99
  single-stranded RNA virus, 99
REST, see Rotavirus Efficacy and Safety Trial (REST)
Reyes syndrome, 82, 95
  “Rice-water” diarrhea, 245
RifamateTM/RifaterTM, 70
RotaTeq vaccine, 235
Rotavirus Efficacy and Safety Trial (REST), 235
RPR, see Rapid plasma reagin (RPR)
S
Salmonella, non-typhoidal, 242–243
  clinical presentation, 242
  etiology, 242
  treatment, 243
    definitive phage type 104 (DT104), 243
    first-line drugs, 243
    fluoroquinolones, 243
Salmonellosis, 242
Salvage therapy, 144–145, 338
S. aureus vaccine, 381
SBE, see Subacute bacterial endocarditis (SBE)
SBP, see Spontaneous bacterial peritonitis (SBP)
SCCmec, see Staphylococcal cassette chromosome mec (SCCmec)
SCT, see Stem cell transplant (SCT)
SENTRY Antimicrobial Surveillance Program, 130
Septic arthritis, 315–319
  etiology, 316–317
    clinical presentation/diagnosis, 317–318
    Coagulase-negative staphylococci, 317
    Enteric gram-negative rods, 317
    Gonococcal septic arthritis, 317
    Hemolytic streptococci, 316
    Meningococcal septic arthritis, 317
organisms isolated in 2407 cases, 316t
  Pneumococcus, 316
  Staphylococcus aureus, 316
  therapy/outcome, 318–319
    duration of therapy, 318–319
    empiric antibiotic therapy, 319t
    joint drainage, 319
Sexually transmitted diseases (STDs), 195–227
  ectoparasitic infections, 226–227
  epididymitis, 216
  genital ulcer disease, 197–205
  HPV, 206–208
  pelvic inflammatory disease, 223–226
  pharyngitis, 215
  proctitis/proctocolitis/enteritis, 216
  urethritis/cervicitis diseases, 208–215
    treatment of urethritis and cervicitis, 212t
  vaginal discharge diseases, 216–223
See also Individual
Sexually transmitted ectoparasitic infections, 226–227
  pediculosis pubis, 226
  ivermectin/permethrin, 226
scabies, 227
  lindane resistance, 227
  Norwegian scabies, 227
  pyrethroid (permethrin) resistance, 227
SHEA, see Society for Healthcare Epidemiology of America (SHEA)
Shigella
  clinical presentation, 244–245
  etiology, 245
  treatment, 245
    ceftriaxone/azithromycin, 245
    effective therapies, 245
    fluoroquinolones/ciprofloxacin, 245
Shigellosis or acute bacillary dysentery, 244
Sinus inflammation, 153–154
Sinusitis, acute
  clinical description
    “double sickening” phenomenon, symptoms, 153
    non-sinus-related diagnoses, CT results, 153
    sinus inflammation, 153
  epidemiology
    children/adults, increased risk factors, 154
  etiology
    bacterial sinusitis, 154
    fungal sinusitis, 154
    viral infection, major cause, 154
Sinusitis, acute (cont.)
treatment
antibiotics, placebo-controlled trials/results, 154–155
short-course therapy/narrow-spectrum agents, recommended, 155
Skin and soft tissue infections (SSTI), 301–311
SMZ/TMP, see Sulfamethoxazole/trimethoprim (SMZ/TMP)
Society for Healthcare Epidemiology of America (SHEA), 23
Solid organ transplant (SOT) recipient, infections, 368–371
etiolologic agents, 372
allograft, 370
chronic recrudescent viral infections, 369
CNS infection, 370
HSV reactivation, 369
intra-abdominal infections, 370
opportunistic organisms, 369
postoperative infections, 369
pre-existent preoperative infections, 369
skin/wound infections, 370
urinary tract infection, 370
immunodeficiencies, 372
cell-mediated/humoral immunity defects, 369
immunosuppressive agents, utilized, 369
liver transplant surgery, 369
prophylaxis/treatment, 371
antifungal treatment, 371
broad-spectrum antimicrobial therapy, 371
ganciclovir prophylaxis, 371
isoniazid prophylaxis, 371
pre-transplant vaccination, 371
TMP–SMX agent, 372
urinary tract prophylaxis, 371
SOT, see Solid organ transplant (SOT) recipient, infections
Space-occupying lesion syndrome, 297–298
diagnosis, 298
etiology, 298
treatment, 298
Spontaneous bacterial peritonitis (SBP), 260–262
clinical presentation, 261
etiology, 261
treatment, 261–262
SSPE, see Subacute sclerosing panencephalitis (SSPE)
SSTI, see Skin and soft tissue infections (SSTI)
SSTI, uncomplicated
abscess
clinical presentation, 309
epidemiology, 307, 309
microbiology, 310
treatment, 307–308
bacterial etiology of skin infections, 302t
bites
clinical presentation, 304
epidemiology, 304
microbiology, 304
treatment, 310
CA-MRSA infection
people at higher risk, 301
TMP-SMX/tetracyclines, treating agents, 304
cellulitis/erysipelas
clinical presentation, 308
epidemiology, 308
microbiology, 308
treatment, 309
folliculitis/furuncle/carbuncle
clinical presentation, 305–306
epidemiology, 306
microbiology, 306
treatment, 306
impetigo
clinical presentation, 304
epidemiology, 304
microbiology, 304
treatment, 305
treatment of skin infections, 302t–313t
Staphylococcal cassette chromosome mec (SCCmec), 36–38
Staphylococcal scalded skin syndrome, 305
Staphylococcus aureus, 36–37, 156, 306
colonizing organism, 36
methicillin resistants, 36
micrococcaceae, 36
PBP2a and MRSA, 37
positive coagulase test, 36
SCCmec (types I–V), 37
synthetic penicillins, 36
virulence factors, 36
See also Gram-positive bacteria, antimicrobial resistance
STDs, see Sexually transmitted diseases (STDs)
St. Elizabeth’s Medical Center, 316
Stem cell transplant (SCT), 361
Stevens–Johnson syndrome, 88
STIs, see Structured treatment interruptions (STIs)
Streptococcus pneumoniae, 157
Streptococcus pneumoniae, 33–36, 152
  antibiotic-resistant strain, 34
  colonizing organism, 34
  in nasopharynx, 34
  phosphorylcholine, 34
  pneumolysin, 34
  prevention
    Pneumovax® and Pnu-Immune®, 36
    7-valent pneumococcal conjugate vaccine (Prevnar®), 36
  serotype identification system, 33
  susceptible to penicillin, 35
  treatment
    cephalosporins, 36
    failure or penicillin allergy, 35
    for infections and resistant, 35
    meningitis, 35
    pneumonia and bacteremia, 35
    vancomycin, 36
  treatment for infections, 35
  type-specific protective immunity, 33
  See also Gram-positive bacteria, antimicrobial resistance
Streptococcus pneumoniae vaccines, 381
Structured treatment interruptions (STIs), 339
Subacute bacterial endocarditis (SBE), 268,
  272–273
Subacute sclerosing panencephalitis (SSPE), 295
  motor dysfunction, 295
  vaccination, 295
Sulfamethoxazole/trimethoprim (SMZ/TMP),
  53–54
“Susceptible dose dependent,” 142
Syphilis, 202–205
  clinical description, 202
  gummas, 202
  latent syphilis, 202
  secondary syphilis, 202
  symptoms, 202
  tertiary (late) syphilis, 202
  treponemes, 202
  epidemiology, 202–203
  HIV, transmission/infection, 203
  men sex with men (MSM), 202
  etiology and diagnosis, 203
  dark-field microscopy or DFA test, 203
  nontreponemal tests, 203
  PCR-based tests, 203
  serologic tests, 203
  treatment, 203–205, 204t
  azithromycin/ceftriaxone, 204
  Jarisch–Herxheimer reaction, 204
  neurosyphilis, 205
  penicillin-allergic patients, 205
  Penicillin G, 203
  primary and secondary syphilis, 205
  second-line therapies, 203
T
TD, see Traveler’s diarrhea (TD)
TEE, see Transesophageal echocardiography (TEE)
Temperature-mediated amplification (TMA),
  210
Tenosynovitis, 213, 317
Thrombotic thrombocytopenic purpura (TTP),
  239
TTP–hemolytic uremic syndrome, 91
TMA, see Temperature-mediated amplification
  (TMA)
TMP-SMX, see Trimethoprim/sulfamethoxazole
  (TMP-SMX)
TNF-α, see Tumor necrosis factor-α (TNF-α)
  inhibitors
TOA, see Tubuloovarian abscess (TOA)
Tonsillitis/pharyngitis
  clinical description, 158–159
  epidemiology, 159
  etiology
    chlamydia and mycoplasma, role of, 160
    clinical prediction rule, 160
    Group A beta-hemolytic streptococcus, 159
    rapid strep testing, cost-effective approach, 160
    respiratory viruses, common cause, 159
  treatment
    group A beta-hemolytic streptococcal tonsillectomy, 160–161
    group A streptococcal carriers, 161
    non-group A streptococcal pharyngitis, 161
Toxic shock syndrome, 36
Transesophageal echocardiography (TEE), 270
Transthoracic echocardiography (TTE), 270
  advantages/disadvantages, 270
Traveler’s diarrhea (TD), 237–238
  clinical presentation, 237
  etiology, 237
  treatment, 238
    azithromycin/rifaximin/loperamide, 238
    bismuth subsalicylate, 238
    empiric antibiotic treatment, 238
    fluoroquinolones, 238
    oral rehydration therapy, 238

Treatment of influenza, 117–120
  antiviral resistance, 120
    drug administration, 120
    NA/M2 mutations, 120
  resistance/cross resistance, 120
    single point mutation, 120
  antivirals: adamantanes, 118
    amantadine and rimantadine, 118
    anticholinergic side effects, 118
    M2 protein (influenza A), 118
    serum concentration, 118
    teratogenic effects, 119
  antivirals: neuraminidase inhibitors
    oseltamivir, 118–119
    zanamivir, 118–119

Trimethoprim/sulfamethoxazole (TMP-SMX), 2, 155, 158, 184–189, 243, 247, 262, 304, 308, 372

Trisomy 21, 156

TST, see Tuberculin skin test (TST)

TTE, see Transthoracic echocardiography (TTE)

TTP, see Thrombotic thrombocytopenic purpura (TTP)

Tuberculin skin test (TST), 74–75, 373

Tuberculosis, 61–76
  drug resistance, 63
    antibiotics resistance (RIF plus INH), 63
    MDR-TB, risk factors, 63
    mutations, spontaneous, 63
    tuberculosis management practices, 63
  epidemiology, 61–63
    cure rate, drug susceptible, 62
    drug resistance/prevalences, 62
    MDR-TB (INHor RIF), 62
    mortality rate, 61
  Mycobacterium tuberculosis, 61
  XDR-TB, 62
  preventive regimens for TB disease, 74–76
    anti-TNF-α antibodies, 74
    candidates for preventive therapy, 75
    ELISA test, 75

HIV-infected individuals, 74
  immunodeficieny, 74
  immunosuppression, severe, 76
  INF-γ, whole blood assay, 74–75
  INH/RIF/PZA, LTBI treatment, 75
  LTBI, treatment, 74
  MDR-TB, risk factors, 76
  Quantiferon®-TB Gold test, 75
  re-infection, 74
  tuberculin skin test, 74–75
  treatment of drug-resistant TB disease, 72–74
  See also Drug-resistant TB disease, treatment
  treatment of drug-susceptible TB disease, 63–72
  See also Drug-susceptible TB disease, treatment

Tubuloovarian abscess (TOA), 224

Tufts-New England Medical Center, 316

Tumor necrosis factor-α (TNF-α) inhibitors, 361
  infections, 373–374
  etiologic agents, 373
  immunodeficiencies, 373
  treatment, 373

Typhoid fever, 243–244
  clinical presentation, 243
  etiology, 244
  treatment, 244
    combined hepatitis A/typhoid fever vaccines, 244
    first-line treatment, 244
    oral vaccine/intramuscular vaccine, 244

U

UAT, see Urinary antigen testing (UAT)

UC, see Ulcerative colitis (UC)

Ulcerative colitis (UC), 254–255

Upper Respiratory Infections (URIs), 151–164

Urethritis diseases, 209–214
  Chlamydia resistance, 214
  clinical description, 209
  CDC 2006 STD treatment guidelines, 209
  diagnosis, 210–211
  gonorrhea or Chlamydia, 211
  gram-negative diplococci, 210
  epidemiology, 209
  etiology, 210
  Chlamydia trachomatis, 210
  Neisseria gonorrhoeae, 210
  gonorrhea resistance, 213–214
chromosomal mutations, 213
drug agents, 213
GASP/GISP, 213
QRNG/QRDR, 213
special considerations, 211–213
disseminated gonorrhea, 213
partner notification, 211
recurrent or persistent urethritis, 212
treatment
erythromycin/ampicillin, 211
GC infections, 211
single-dose azithromycin, 211
Urinary antigen testing (UA T), 173
Urinary tract infections (UTI), 45, 183–193
asymptomatic bacteriuria, 192–193
catheter-associated UTI, 191–192
definition/presentation/epidemiology, 191
prevention, 191
treatment, 192
complicated UTI, 189–190
cystitis, 184–186
definition/presentation/epidemiology, 184
diagnosis, 184–185
therapy, 185–186
pyelonephritis, 186–189
definition/presentation/epidemiology, 186
diagnosis, 186–187
therapy, 187–189
recurrent UTI, 190–191
definition/epidemiology, 190
prevention, 190–191
URIs, see Upper Respiratory Infections (URIs)
URIs and acute bronchitis
acute bronchitis
clinical description, 162
epidemiology, 162
etiology, 163
evaluation, 163
treatment, 163–164
acute otitis media
clinical description, 155
epidemiology, 155–156
etiology, 156–157
treatment, 157–158
acute sinusitis
clinical description, 153
epidemiology, 154
etiology, 154
treatment, 154–155
common cold
clinical description, 151
epidemiology, 152
etiology, 152
treatment, 153
tonsillitis/pharyngitis
clinical description, 158–159
epidemiology, 159
etiology, 159–160
treatment, 160–161
uncomplicated infections
mechanisms of transmission, 152
UTI, see Urinary tract infections (UTI)
V
Vaccination, 79, 81–84, 98, 103, 121–123, 196, 258, 293, 295, 371, 386
Vaginal discharge, diseases characterized by, 216–223
bacterial vaginosis (BV), 217–218
clinical description, 217
diagnosis, 218
etiology, 217–218
treatment, 218
treatment of vaginitis, 219–220
Trichomoniasis, 218–222
diagnosis, 221
etiology and epidemiology, 221
treatment, 222
vulvovaginal candidiasis (VVC), 222–223
clinical description, 222
diagnosis, 223
etiology and epidemiology, 222
treatment, 223
Valacyclovir therapy, 91
Vancomycin-intermediate S. aureus (VISA) infections, 12, 39–40
Vancomycin-resistant enterococci (VRE) infections, 22, 40–42, 272, 274, 366, 371, 383, 385
Vancomycin-resistant S. aureus (VRSA) infections, 12, 39–40
Vancomycin-susceptible Enterococcus (VSE), 41
VAP, see Ventilator-associated pneumonia (VAP)
Varicella, 94–95
incubation period, 95
infection complications, 95
perinatal infection, 95
symptoms, 94–95
Varicella Zoster Immune Globulin (VZIG), 95, 97–98
Varicella zoster virus (VZV), 94–98, 292
antiviral therapy, 96–97
  acyclovir, 96
  chronic corticosteroids, 96
  famciclovir, 96
  neuralgia, 96
  placebo-controlled trial, 96
  valacyclovir, 96
clinical syndromes, 94–95
  herpes zoster, 95
  varicella, 94–95
diagnosis, 96
epidemiology, 94
  secondary varicella, 94
  serologic immunity, 94
  VZV transmission, 94
prevention, 97–98
  post-exposure prophylaxis, 97–98
  vaccination, 98
VDRL, see Venereal Disease Research Laboratory (VDRL)
Venereal Disease Research Laboratory (VDRL), 203, 288
Ventilator-associated pneumonia (VAP), 23, 37, 39, 54, 177–180
Vibrio cholerae, 245–246
  clinical presentation, 245–246
  etiology, 246
  treatment, 246
  doxycycline/quinolone resistance, 246
Vibrio infections, 308
Viral load testing
  PCR or bDNA, 338
Viral meningitis, 284
Viral prophylaxis, 364
VISA, see Vancomycin-intermediate S. aureus (VISA) infections
Vogt–Koyanagi–Harada syndrome, 287
Voriconazole, 127, 139, 143, 145, 277, 368
VRE, see Vancomycin-resistant enterococci (VRE) infections
VRSA, see Vancomycin-resistant S. aureus (VRSA) infections
VSE, see Vancomycin-susceptible Enterococcus (VSE)
VZIG, see Varicella Zoster Immune Globulin (VZIG)
VZV, see Varicella zoster virus (VZV)

W
Wait and see Protocol (WASP), 157
WASP, see Wait and see protocol (WASP)
Waterhouse–Friderichsen syndrome, 283
Western blot assay, 288, 334
West Nile virus (WNV), 292
Wet prep microscopy, 218, 221
WHO, see World Health Organization (WHO)
WNV, see West Nile virus (WNV)
World Health Organization (WHO), 6, 121, 213, 244, 385
Wound cultures, 311

X
XDR-TB, see Extensively resistant tuberculosis (XDR-TB)

Y
Yersinia, 246–247

Z
Zygomycosis, 127–128, 141